Home
This site is intended for healthcare professionals

Obstructive Sleep Apnea Care Pathways Translating Cardiometabolic Risk into Longitudinal Management: Module 6 Contextual and Equitable Care

Share

Description

This activity is supported by an independent education grant from Lilly. This online education program has been designed for healthcare professionals in the U.S.

In this module, Dr. Mehra addresses the systemic and logistical barriers that frequently prevent patients from completing OSA testing and sustaining treatment. Clinicians will learn how to navigate prior authorization hurdles, manage durable medical equipment (DME) access issues across varying insurance types, and utilize non-stigmatizing communication to build realistic, equity-adapted care plans.

Session Highlights

  • Navigate logistical barriers—including prior authorization criteria, high deductibles, and durable medical equipment (DME) supplier restrictions—by tailoring the access plan to the patient's specific insurance coverage (e.g., Commercial, Medicare, Medicaid).
  • Utilize patient-centered, non-stigmatizing communication to identify practical obstacles to testing or CPAP setup early, establishing equity-adapted care strategies that improve long-term adherence.

Prefer to watch in Spanish? Click Here

Who Should Participate?

This program is designed for healthcare professionals who seek to incorporate structured OSA screening and diagnostic activation into routine cardiometabolic management workflows.

  • Primary Care Physicians and Family Medicine Practitioners
  • Nurse Practitioners
  • Physician Assistants

This is Module Six of Six, See Modules 1, 2, 3, 4 and 5 Here.

Prefer to read? See our Key Clinical Summary Here.

Faculty

Dr Reena Mehra

Dr Reena Mehra, MD, MS is an Associate Professor of Medicine at Case Western Reserve University School of Medicine and a staff physician at the Cleveland Clinic, where she serves as the Director of Sleep Disorders Research within the Neurological Institute's Sleep Center. Her extensive research portfolio focuses on the intersection of sleep and cardiovascular health, specifically investigating the relationship between sleep-disordered breathing and abnormal cardiac electrophysiology. Through both epidemiological analyses and clinical trials, she explores how various sleep disorders contribute to cardiovascular disease, establishing her as a key contributor to the understanding of the hemodynamic and mechanistic links between sleep apnea and cardiac outcomes.

Disclosures

Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to Partners policies.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.

Dr Reena Mehra, Faculty for this activity has the following relevant financial relationships: Consultant, Advisory Board, Educational Media - Amgen, Apnimed, Centessa, Eli Lilly, Haymarket Media, and Mineralys.

The MedAll staff, program planners, and reviewers have no relevant financial relationships with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and MedAll. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

Partners designates this live activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Associate Continuing Education

Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.25 ANCC contact hours.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information

There is no fee for this educational activity.

This continuing education activity is active starting September 11th 2026, and will expire on July 1st 2028.

Learning objectives

1: Evaluate the bidirectional relationship between obesity and OSA to inform cardiometabolic risk assessment, demonstrating accurate identification of OSA risk within ≥75% of post-activity case-based assessments.

2: Identify patients at increased risk of OSA using clinical features and comorbidities in primary care, achieving appropriate risk stratification in ≥75% of applied clinical scenarios.

3: Apply workflow-compatible screening and triage strategies to support early identification of OSA, demonstrating correct use of structured tools and decision pathways in ≥75% of simulation-based exercises.

4: Select appropriate diagnostic and referral pathways, including HSAT, based on clinical presentation and practice context, achieving appropriate pathway activation in ≥75% of case-based assessments.

5: Apply longitudinal management and treatment progression strategies in OSA care planning to support sustained disease control, demonstrating appropriate decision-making in ≥70% of longitudinal case exercises.

6: Apply contextually adapted care strategies that account for socioeconomic and practice-setting factors to support equitable diagnostic and management decisions in OSA, demonstrating appropriate decision-making in ≥70% of applied scenarios.

Similar communities

View all

Similar events and on demand videos

Computer generated transcript

Warning!
The following transcript was generated automatically from the content and has not been checked or corrected manually.

So what are the aspects uh in terms of context and equitable care? So, let's look at the clinical pathway and see where the areas are where the pathway can break. So this can occur during the screening phase, ordering of the test, confirmation of the diagnosis, initiation of treatment, and then the management in terms of the long-term care. So, what are the inherent challenges to every step of this path? So with screening, uh, with that aspect, uh, if there's no protocol in place, if there's uncertainty in terms of How to approach screening, what tools should be used, or if there's competing priorities. So, if it is not um on the mind of the clinician or the patient, and uh the visit is consumed by other uh competing priorities, and then it's, it's not front of mind and therefore not discussed. So the outcome then um is uh risk is identified, but the next step um is not activated. In terms of the testing, The potential barriers there are cost, scheduling, um, and also dealing with prior authorization, particularly if in laboratory polysomnography is pursued as an initial step. So in this case, uh, the order can be placed, uh, but then if, if the cost and the scheduling and a prior authorization of these aspects are not addressed, then the testing may not be completed. In terms of the diagnostics, so if the diagnosis of obstructive sleep apnea is confirmed, there can be challenges with access to DME, uh, with coverage of the device and not understanding the degree of coverage by the insurance in terms of health literacy being compromised on the, on the, uh, part of the patient in terms of them. Um, not understanding the importance of the diagnosis of sleep apnea and its impact on health and disease. So the results here are available, but the treatment is not initiated, so that connection is not being made for that next step. The treatment initiation phase can come with challenges of patient adherence to the device, and that can be due to mask fit issues, so the mask interface, um, other issues with the positive airway pressure device such as pressure intolerance, nasal congestion, Uh, claustrophobia. So, uh, sometimes anticipating what those issues are and, um, in terms of managing expectations, letting patients know that these symptoms or issues may occur. Um, well, at least, uh, on the part of the patient, make it, uh, understandable to them so they know, oh, this is to be expected, this could happen, and I should reach out to my, um, physician to help work through these issues. And then follow-up gaps. So sometimes treatment is initiated and a follow-up visit has not been made. So, in this case, positive airway pressure therapy started, but the usage is not sustained. And in terms of long-term care, There can be silos in terms of care, um, issues with handoffs, fragmentation of care. So, this disconnected care in terms of obstructive sleep apnea management can then, uh, impact cardio metabolic management as well. So, things are intertwined and there's really a need for integrated longitudinal care for patients with obstructive sleep apnea. And there are the practical aspects of coverage and access considerations with obstructive sleep apnea. So understanding the insurance coverage type is important. So checking the insurance early and understanding commercial, Medicare, Medicaid, um, if There's high deductibles involved, uninsured. So, this can help address concerns of cost and amount of deductible and eligibility. And a lot of this is, again, managing expectations. So, if the patient is not aware that there could be some of these issues, then They may get disillusioned with continuing in the clinical care path. Prior authorization, so building the clinical rationale into the order or referral, uh, in terms of providing the justification, um, and so the barriers are, um, understanding the criteria, actually entering, uh, these data and delays that can, um, occur with prior authorization. In terms of the testing pathway, uh, confirming whether home sleep apnea testing versus in-lab polysomnography or specialist referral is realistically accessible, and the barriers there can be, um, issues with, uh, the network, the wait time, and, and the location. And in terms of treatment access, confirming the DME supplier, so oftentimes there are many DMEs available. Some of them are actually um aligned with certain insurers as well, and some of them may geographically cover patients in certain areas versus others. So understanding those aspects are very, that's very important. Understanding the degree of equipment coverage, uh, arranging for early follow-up is important, so within 31 to 90 days. Uh, and the barriers here can be, in some instances, DME, this having the supplies, ensuring optimal adherence. So the best pathway is the one the patient can successfully complete. And so being aware of these different Barriers and logistical issues, uh, is, is very important. So, let's review some equity adapted strategies that fit in the primary care model. So the primary care action uh could be to ask early. So why, what might make testing or treatment hard for you to complete. Um, so this is Potentially an access to care, uh, issue or access to diagnostics. So, you know, is there issue getting a ride to come in for the in-lapse sleep study? Um, is there severe arthritis that may make it difficult for somebody to, you know, uh, Connect the um um uh electrodes and the, the elements of the home sleep apnea test. So, addressing those barriers in terms of if there's a cost issue, caregiving issue, or a transportation issue, um, you know, is good to, to address early on. Adapting the pathway as needed, so choosing the feasible route, that is, you know, home sleep apnea testing or in-lab testing, uh, navigating that path or referring to the specialist. So there can, um, these can be addressed by, uh, proactively looking into insurance and potential issues with wait time. And documenting clearly is helpful and including the symptoms that are prompting the testing to be done, the risk factors, the comorbidities, especially cardio metabolic, neurologic, the clinical rationale for the study, and, uh, and proactively, you know, attempting to address issues with, with, um, you know, prior authorization in this way. And then closing the loop. So scheduling. Uh, the opportunity to review the results of the study, uh, with the patient and using that as a way to explain the results and the importance of treatment and the implications of not treating obstructive sleep apnea. The first treatment check, uh, before the patient leaves the office is important so that they know that this is scheduled, and uh they, they don't fall through the cracks. So, there can be um attrition, DME delays and adherence. So, using this strategy will help to uh mitigate those barriers. So, integrating this equity adapted care uh is not a lower standard of care. It's the same clinical standard with a more realistic access plan. And in terms of patient-centered scripts and addressing the barriers without stigma, this is important because we are allying with our patients to identify sleep apnea and treat it. So, Uh, normalizing, uh, the barriers. So, uh, saying many patients run into practical barriers with sleep testing or CPAP setup. So, uh, and that's also managing expectations there, asking what might make it hard to complete the sleep test or start treatment. You know, I want to help you with any issues that may come up proactively. Adapting the plan. So knowing that now helps us then choose the pathway you are more likely to complete. And it is a partnership with the patient in terms of uh in terms of diagnosing and treating sleep apnea. So we're, we'll work through the insurance equipment and follow-up steps together.